Medical cannabis is a massively growing market in Europe – but it is not classified or regulated within the usual framework for medicines. There is a lack of European regulations, intended to harmonize marketing of medicines, for either CBD or THC-based cannabis products.
Yet, the reality is that medical cannabis has shown efficacy in trials and is being deployed legally in medical settings as a therapeutic for conditions ranging from cancer to AIDS
Major global cannabis exporters, including those from Canada and North America, cannot tap into a common regulatory pathway to European markets.
Cannabis is a massive opportunity, but supplying the different European markets can be a
challenge. To help address the challenge, Arriello has produced this country-by-country guide to the patchwork of regulations across Europe.
Example – Pennsylvania has approved cannabis use for these conditions: ⃣ Amyotrophic Lateral Sclerosis;
⃣ Crohn’s disease;
⃣ Damage to the nervous tissue of the spinal
cord with objective neurological indication of
⃣ HIV (Human Immunodeficiency Virus)/AIDS
(Acquired Immune Deficiency Syndrome);
⃣ Huntington’s disease;
Inflammatory Bowel disease;
⃣ Intractable seizures;
⃣ Multiple sclerosis;
⃣ Parkinson’s disease;
⃣ Post-traumatic stress disorder;
⃣ Severe chronic or intractable pain of neuropathic
origin or severe chronic or intractable pain in which conventional therapeutic intervention and opiate therapy is contraindicated or neffective;
⃣ Sickle cell anemia.
Continue at: https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=2ahUKEwiPyszf0OD1AhVQzoUKHZU4BW8QFnoECAQQAQ&url=https%3A%2F%2Fwww.arriello.com%2Fwp-content%2Fuploads%2F2021%2F07%2Fcannabisguide-2021-digital.pdf&usg=AOvVaw2ljTZVDoRt6KvZ5uNNUJPs
The text above is owned by the site above referred.
Here is only a small part of the article, for more please follow the link